{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:36:19Z","timestamp":1759541779349},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s00415-005-4007-6","type":"journal-article","created":{"date-parts":[[2005,10,12]],"date-time":"2005-10-12T15:04:22Z","timestamp":1129129462000},"page":"iv32-iv36","source":"Crossref","is-referenced-by-count":9,"title":["Levodopa therapy from the neuroprotection viewpoint"],"prefix":"10.1007","volume":"252","author":[{"given":"Tomoyoshi","family":"Kondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"4007_CR1","first-page":"77","volume":"5","author":"Cohen","year":"1984","unstructured":"Cohen G (1984) Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5(1):77\u201382","journal-title":"Neurotoxicology"},{"key":"4007_CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","volume":"989","author":"Burke","year":"2003","unstructured":"Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) 3.4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson\u2019s disease pathogenesis. Brain Res 989(2):205\u2013213","journal-title":"Brain Res"},{"key":"4007_CR3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbrc.2005.04.124","volume":"332","author":"Machida","year":"2005","unstructured":"Machida Y, Chiba T, Takayanagi A, Tanaka Y, Asanuma M, Ogawa N, Koyama A, Iwatsubo T, Ito S, Jansen PH, Shimizu N, Tanaka K, Mizuno Y, Hattori N (2005) Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem Biophys Res Commun 332(1):233\u2013240","journal-title":"Biochem Biophys Res Commun"},{"key":"4007_CR4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1353-8020(01)00023-2","volume":"8","author":"Rajput","year":"2001","unstructured":"Rajput AH (2001) Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 8(2):95\u2013100","journal-title":"Parkinsonism Relat Disord"},{"key":"4007_CR5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson","year":"2002","unstructured":"Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13):1653\u20131661","journal-title":"JAMA"},{"key":"4007_CR6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"Whone","year":"2003","unstructured":"Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group (2003) Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54(1):93\u2013101","journal-title":"Ann Neurol"},{"key":"4007_CR7","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351(24):2498\u20132508","journal-title":"N Engl J Med"},{"key":"4007_CR8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1046\/j.1471-4159.1997.68010328.x","volume":"68","author":"Haavik","year":"1997","unstructured":"Haavik J, Almas B, Flatmark T (1997) Generation of reactive oxygen species by tyrosine hydroxylase: a possible contribution to the degeneration of dopaminergic neurons? J Neurochem 68(1):328\u2013332","journal-title":"J Neurochem"},{"key":"4007_CR9","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","volume":"53","author":"Jenner","year":"2003","unstructured":"Jenner P (2003) Oxidative stress in Parkinson\u2019s disease. Ann Neurol 53 (Suppl 3):S26\u2013S36","journal-title":"Ann Neurol"},{"key":"4007_CR10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ana.410320616","volume":"32","author":"Fahn","year":"1992","unstructured":"Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson\u2019s disease: evidence supporting it. Ann Neurol 32(6):804\u2013812","journal-title":"Ann Neurol"},{"key":"4007_CR11","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1046\/j.1471-4159.1998.70062406.x","volume":"70","author":"McLaughlin","year":"1998","unstructured":"McLaughlin BA, Nelson D, Erecinska M, Chesselet MF (1998) Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J Neurochem70(6):2406\u20132415","journal-title":"J Neurochem"},{"key":"4007_CR12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1471-4159.1996.66020501.x","volume":"66","author":"Han","year":"1996","unstructured":"Han SK, Mytilineou C, Cohen G (1996) L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 66(2):501\u2013510","journal-title":"J Neurochem"},{"key":"4007_CR13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/jpet.102.042267","volume":"304","author":"Mytilineou","year":"2003","unstructured":"Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304(2):792\u2013800","journal-title":"J Pharmacol Exp Ther"},{"key":"4007_CR14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/mds.870010109","volume":"1","author":"Quinn","year":"1986","unstructured":"Quinn N, Parkes D, Janota I, Marsden CD (1986) Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1(1):65\u201368","journal-title":"Mov Disord"},{"key":"4007_CR15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1353-8020(01)00023-2","volume":"8","author":"Rajput","year":"2001","unstructured":"Rajput AH (2001) Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 8(2):95\u2013100","journal-title":"Parkinsonism Relat Disord"},{"key":"4007_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0304-3940(94)90603-3","volume":"25","author":"Ogawa","year":"1994","unstructured":"Ogawa N, Asanuma M, Kondo Y, Kawada Y, Yamamoto M, Mori A (1994) Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 25; 171(1\u20132):55\u201358","journal-title":"Neurosci Lett"},{"key":"4007_CR17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410430504","volume":"43","author":"Murer","year":"1998","unstructured":"Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43(5):561\u2013575","journal-title":"Ann Neurol"},{"key":"4007_CR18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.56.suppl_5.S1","volume":"56","author":"Olanow","year":"2001","unstructured":"Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson\u2019s disease (2001): treatment guidelines. Neurology 56(11 Suppl 5):S1\u2013S88","journal-title":"Neurology"},{"key":"4007_CR19","first-page":"421","volume":"42","author":"Miziuno","year":"2002","unstructured":"Miziuno Y, Okuma Y, Kikuchi S, Kuno S, Hashimoto T, Hasegawa K, Mano Y, Miwa H, Murata M, Yamamoto M, Yokochi F, Okiyama R, Kanazawa A, Shinpo K, Chuma T, Higashi T, Maruyama T, Mizuta E, Yamazaki S; Ad Hoc Committee on the Guidelines for the Treatment of Parkinson\u2019s Disease, Japanese Neurological Society (2002) A guideline for the treatment of Parkinson\u2019s disease. Rinsho Shinkeigaku 42(5):421\u2013494","journal-title":"Rinsho Shinkeigaku"},{"key":"4007_CR20","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.bjp.0702673","volume":"127","author":"Coldwell","year":"1999","unstructured":"Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN (1999) Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127(7):1696\u20131702","journal-title":"Br J Pharmacol"},{"key":"4007_CR21","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00019052-200312001-00002","volume":"16","author":"Jenner","year":"2003","unstructured":"Jenner P (2003) Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson\u2019s disease. Curr Opin Neurol 16(Suppl 1):S3\u2013S7","journal-title":"Curr Opin Neurol"},{"key":"4007_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0733-8619(18)30213-5","volume":"10","author":"Hoehn","year":"1992","unstructured":"Hoehn MM (1992) The natural history of Parkinson\u2019s disease in the prelevodopa and post-levodopa eras. Neurol Clin 10(2):331\u2013339","journal-title":"Neurol Clin"},{"key":"4007_CR23","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484\u20131491","journal-title":"N Engl J Med"},{"key":"4007_CR24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.410440117","volume":"44","author":"Sawada","year":"1998","unstructured":"Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Kimura J, Shimohama S (1998) Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 44(1):110\u2013119","journal-title":"Ann Neurol"},{"key":"4007_CR25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/exnr.1998.6952","volume":"154","author":"Kobayashi","year":"1998","unstructured":"Kobayashi S, Ogren SO, Hoffer BJ, Olson L (1998) Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum. Exp Neurol 154(2):302\u2013314","journal-title":"Exp Neurol"},{"key":"4007_CR26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000077451","volume":"71","author":"Ohta","year":"2004","unstructured":"Ohta K, Fujinami A, Kuno S, Sakakimoto A, Matsui H, Kawahara Y, Ohta M (2004) Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 71(3):162\u2013168","journal-title":"Pharmacology"},{"key":"4007_CR27","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1046\/j.1460-9568.2002.02256.x","volume":"16","author":"Guo","year":"2002","unstructured":"Guo H, Tang Z,Yu Y, Xu L, Jin G, Zhou J (2002) Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur J Neurosci 16(10):1861\u20131870","journal-title":"Eur J Neurosci"},{"key":"4007_CR28","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1523\/JNEUROSCI.20-22-08643.2000","volume":"20","author":"Bozzi","year":"2000","unstructured":"Bozzi Y, Vallone D, Borrelli E (2000) Neuroprotective role of dopamine against hippocampal cell death. J Neurosci 20(22):8643\u20138649","journal-title":"J Neurosci"},{"key":"4007_CR29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1460-9568.2003.02547.x","volume":"17","author":"Tripanichkul","year":"2003","unstructured":"Tripanichkul W, Stanic D, Drago J, Finkelstein DI, Horne MK (2003) D2 Dopamine receptor blockade results in sprouting of DA axons in the intact animal but prevents sprouting following nigral lesions. Eur J Neurosci 17(5):1033\u20131045","journal-title":"Eur J Neurosci"},{"key":"4007_CR30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0014-5793(92)81430-T","volume":"313","author":"Okazawa","year":"1992","unstructured":"Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I (1992) Dopaminergic stimulation up-regulates the in vivo expression of brainderived neurotrophic factor (BDNF) in the striatum. FEBS Lett 313(2):138\u2013142","journal-title":"FEBS Lett"},{"key":"4007_CR31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.wad.0000126614.87955.79","volume":"18","author":"Lytle","year":"2004","unstructured":"Lytle ME, Vander Bilt J, Pandav RS, Dodge HH, Ganguli M (2004) Exercise level and cognitive decline: the MoVIES project. Alzheimer Dis Assoc Disord 18:57\u201364","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"4007_CR32","first-page":"248","volume":"11","author":"Hiwatani","year":"2005","unstructured":"Hiwatani H, Miwa H, Kondo T, Kajimoto Y (2005) Effects of leg muscle on Parkinson\u2019s disease patients. Parkinsonism Relat Disord 11(Suppl 2):248","journal-title":"Parkinsonism Relat Disord"},{"key":"4007_CR33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/B:MEBR.0000027416.13070.c3","volume":"19","author":"Mabandla","year":"2004","unstructured":"Mabandla M, Kellaway L, St Clair Gibson A, Russell VA (2004) Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle. Metab Brain Dis 19:43\u201350","journal-title":"Metab Brain Dis"},{"key":"4007_CR34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2003.08.017","volume":"184","author":"Smith","year":"2003","unstructured":"Smith AD, Zigmond MJ (2003) Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp Neurol 184:31\u201339","journal-title":"Exp Neurol"},{"key":"4007_CR35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0306-4522(03)00096-4","volume":"119","author":"Tillerson","year":"2003","unstructured":"Tillerson JL, Caudle WM, Reveron ME, Miller GW (2003) Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson\u2019s disease. Neuroscience 119:899\u2013911","journal-title":"Neuroscience"},{"key":"4007_CR36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1471-4159.2003.01657.x","volume":"85","author":"Cohen","year":"2003","unstructured":"Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ (2003) Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem 85:299\u2013305","journal-title":"J Neurochem"},{"key":"4007_CR37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jnr.20162","volume":"77","author":"Fisher","year":"2005","unstructured":"Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul CK, Jakowec MW (2005) Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 77:378\u2013390","journal-title":"J Neurosci Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-4007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-005-4007-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-4007-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:04:05Z","timestamp":1559055845000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-005-4007-6"}},"subtitle":["From a clinical outlook"],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":37,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["4007"],"URL":"https:\/\/doi.org\/10.1007\/s00415-005-4007-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}